StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Krystal Biotech r&d expenses

Research and development expenses are spending on new products and technology.

Krystal Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $59.23M, up 6.3% year over year. For fiscal 2025 it was $58.05M, up 8.3% from the year before. The highest annual figure on record is $58.05M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.05M+8.3%
FY2024Dec 31, 2024$53.58M+15.4%
FY2023Dec 31, 2023$46.43M+9.4%
FY2022Dec 31, 2022$42.46M+52.3%
FY2021Dec 31, 2021$27.88M+55.5%
FY2020Dec 31, 2020$17.94M+14.9%
FY2019Dec 31, 2019$15.62M+101.2%
FY2018Dec 31, 2018$7.76M+141.9%
FY2017Dec 31, 2017$3.21M+332.9%
FY2016Dec 31, 2016$741.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.52M+0.7%
Q1 FY2026Mar 31, 2026$15.33M+7.5%
Q4 FY2025Dec 31, 2025$14.79M+9.4%
Q3 FY2025Sep 30, 2025$14.59M+7.9%
Q2 FY2025Jun 30, 2025$14.41M-7.5%
Q1 FY2025Mar 31, 2025$14.26M+30.1%
Q4 FY2024Dec 31, 2024$13.53M+19.0%
Q3 FY2024Sep 30, 2024$13.51M+27.1%
Q2 FY2024Jun 30, 2024$15.58M+28.3%
Q1 FY2024Mar 31, 2024$10.96M-10.8%
Q4 FY2023Dec 31, 2023$11.37M+5.9%
Q3 FY2023Sep 30, 2023$10.63M-7.7%
Q2 FY2023Jun 30, 2023$12.14M+11.5%
Q1 FY2023Mar 31, 2023$12.29M+31.9%
Q4 FY2022Dec 31, 2022$10.74M+19.2%
Q3 FY2022Sep 30, 2022$11.52M+89.4%
Q2 FY2022Jun 30, 2022$10.89M+65.2%
Q1 FY2022Mar 31, 2022$9.31M+50.2%
Q4 FY2021Dec 31, 2021$9.01M+58.8%
Q3 FY2021Sep 30, 2021$6.08M+19.2%
Q2 FY2021Jun 30, 2021$6.59M+81.2%
Q1 FY2021Mar 31, 2021$6.20M+75.9%
Q4 FY2020Dec 31, 2020$5.67M+30.4%
Q3 FY2020Sep 30, 2020$5.10M+31.3%
Q2 FY2020Jun 30, 2020$3.64M-13.7%
Q1 FY2020Mar 31, 2020$3.53M+11.3%
Q4 FY2019Dec 31, 2019$4.35M+55.2%
Q3 FY2019Sep 30, 2019$3.89M+103.0%
Q2 FY2019Jun 30, 2019$4.22M+176.5%
Q1 FY2019Mar 31, 2019$3.17M+108.4%
Q4 FY2018Dec 31, 2018$2.80M+157.5%
Q3 FY2018Sep 30, 2018$1.91M+41.3%
Q2 FY2018Jun 30, 2018$1.53M+241.9%
Q1 FY2018Mar 31, 2018$1.52M+376.5%
Q4 FY2017Dec 31, 2017$1.09M+170.6%
Q3 FY2017Sep 30, 2017$1.36M+462.2%
Q2 FY2017Jun 30, 2017$446.00K–
Q1 FY2017Mar 31, 2017$319.00K–
Q4 FY2016Dec 31, 2016$402.00K–
Q3 FY2016Sep 30, 2016$241.00K–

More Krystal Biotech figures

See a number that looks wrong?